NCCN Guidelines® Insights - Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer, Version 3.2024

The NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer provide multidisciplinary diagnostic workup, staging, and treatment recommendations for this disease. These NCCN Guidelines Insights detail how the evolution of the use of PARP inhibitors as maintenance and single-agent regimens for the treatment of ovarian cancer informed panel recommendations in the guidelines.

Target Audience

This journal article is designed to meet the educational needs of oncologists, nurses, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Integrate into professional practice the updates to the NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer.
  • Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Ovarian Cancer/Fallopian Tube Cancer/Primary Peritoneal Cancer.
Additional information
Supporters: 

This activity is supported by educational grants from AstraZeneca; Bristol Myers Squibb; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Seagen. This activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by an independent educational grant from Merck & Co., Inc., Rahway, NJ, USA.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
10/10/2024
Course expires: 
10/10/2025
Cost:
$0.00

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Individuals Who Provided Content Development and/or Authorship Assistance

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Andrew Berchuck, MD, Panel Member
Sharon Robertson, MD, MPH, Panel Member
Shitanshu Uppal, MBBS, MBA, Panel Member
Frankie Jones, Guidelines Layout Specialist, NCCN
Emily Kovach, Guidelines Layout Specialist, NCCN
Lisa Hang, PhD, Oncology Scientist/Senior Medical Writer, NCCN
Swathi Ramakrishnan, PhD, Oncology Scientist/Medical Writer, NCCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Deborah K. Armstrong, MD, Panel Chair, has disclosed serving as a scientific advisor for AstraZeneca Pharmaceuticals LP and GSK; and receiving grant/research support from AstraZeneca Pharmaceuticals LP and Eisai Inc.
Ronald D. Alvarez, MD, MBA, Panel Vice Chair, has disclosed serving as a scientific advisor for AstraZeneca Pharmaceuticals LP, GSK, and Myriad Genetic Laboratories, Inc.
Joyce Liu, MD, MPH, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi-Sankyo Co., Eisai Inc., Genentech, Inc., GSK, and Zentalis.
Floor J. Backes, MD, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP, BioNTech, Clovis Oncology, Daiichi-Sankyo Co., Eisai Inc., EMD Serono, GSK, ImmunoGen, Inc., Merck & Co., Inc., and Myriad Genetic Laboratories, Inc.; receiving grant/research support from AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc., ImmunoGen, Inc., Merck & Co., Inc., Natera, Inc., and Tempus; and serving as a scientific advisor for AstraZeneca Pharmaceuticals LP, BioNTech, Clovis Oncology, Daiichi-Sankyo Co., Eisai Inc., EMD Serono, GSK, ImmunoGen, Inc., and Merck & Co., Inc.
Joshua Cohen, MD, Panel Member, has disclosed receiving consulting fees from and serving as a scientific advisor for ImmunoGen, Inc., and AstraZeneca Pharmaceuticals LP.
Rachel Grisham, MD, Panel Member, has disclosed receiving consulting fees from AstraZeneca Pharmaceuticals LP; and receiving honoraria from Cardinal Health, GSK, Myriad Genetic Laboratories, Inc., and Verastem.
Charles A. Leath III, MD, MSPH, Panel Member, has disclosed receiving grant/research support from AbbVie, Inc., Agenus, AstraZeneca Pharmaceuticals LP, Celsion, Corcept Therapeutics, GSK, Merck & Co., Inc.; receiving consulting fees from Celsion, GSK, and Merck & Co., Inc.; and serving as a scientific advisor for Pfizer Inc.
Lainie Martin, MD, Panel Member, has disclosed serving as a scientific advisor for Daiichi-Sankyo Co., ImmunoGen, Inc., and SUTRO Biopharma, Inc.
Daniela Matei, MD, Panel Member, has disclosed receiving consulting fees from CVS Health and GSK; and receiving grant/research support from PinotBio Inc., Eisai Inc., Acrivon Therapeutics, Shattuck Labs, and Merck & Co. Inc.
David S. Miller, MD, Panel Member, has disclosed receiving consulting fees from AbbVie, Inc., Agenus Inc., AstraZeneca Pharmaceuticals LP, Asymmetric Therapeutics, LLC, Boston Biomedical, Eisai Inc., EMD Serono, GSK, ImmunoGen, Inc., Incyte Corporation, iTeos Therapeutics, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Myriad Genetic Laboratories, Inc., Novartis Pharmaceuticals Corporation, Novocure, Seagen Inc., and Tarveda Therapeutics; receiving grant/research support from Advaxis Inc., Advenchen Laboratories, LLC, Aeterna Zentaris Inc., Agenus Inc., Akeso, Inc., Aprea Therapeutics AB, AstraZeneca Pharmaceuticals LP, EMD Serono, ImmunoGen, Inc., Incyte Corporation, Janssen Pharmaceutica Products, LP, Karyopharm Therapeutics, Leap Therapeutics, Inc., Mateon Therapeutics, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Novartis Pharmaceuticals Corporation, NVISION, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Syros Pharmaceuticals, TESARO, Inc., TRACON Pharmaceuticals, Inc., US Biotest, Inc., and Xenetic Biosciences, Inc.; and serving on the product/speakers bureau for Clovis Oncology and Genentech, Inc.
Lisa Barroilhet, MD, Panel Member, has disclosed serving as a scientific advisor for Merck & Co., Inc.
Andrea Wahner Hendrickson, MD, Panel Member, has disclosed receiving grant/research support from Amgen Inc., Aravive, Inc., AstraZeneca Pharmaceuticals LP, Harpoon Therapeutics, Inc., ProLynx, and TESARO, Inc.; and serving as a scientific advisor for Oxcia AB.

View all of the conflicts of interest for the NCCN Guidelines panel

NCCN Staff Disclosures

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. 

Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-24-011-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until October 10, 2025. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To access this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for article and certificate viewing/printing